Gland Pharma is one of the fastest growing generic injectables-focused companies, selling its products primarily under a business to business (B2B) model in over 60 countries including the United States, Europe, Canada, Australia, India and the Rest of the world. The company was established in Hyderabad, India in 1978 and has expanded from liquid parenterals to cover other elements of the injectables value chain, including contract development, own development, dossier preparation and filing, technology transfer and manufacturing across a range of delivery systems, including liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops. Gland Pharma has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 22 production lines and three API facilities. As of March 31, 2020, it had manufacturing capacity for finished formulations of approximately 755 million units per annum. As of March 31, 2020, the company and its partners had 265 ANDA filings in the United States, of which 204 were approved and 61 were pending approval. The 265 ANDA filings comprise 189 ANDA filings for sterile injectables, 50 for oncology and 26 for ophthalmics related products.
Gland Pharma IPO Dates & Price Band: (Tentative)
| IPO Open: | 09 November 2020 |
| IPO Close: | 11 November 2020 |
| IPO Size: | Approx Rs.6480 Crore (Approx) |
| Face Value: | Rs.1 Per Equity Share |
| Price Band: | Rs.1490 - Rs.1500 Per Share |
| Listing on: | BSE & NSE |
| Retail Portion: | 35% |
| Equity: | 43,196,968 Shares |
Gland Pharma IPO Market Lot:
| Lot Size: | Minimum 10 Shares & Maximum 130 Shares |
| Minimum Amount: | Rs.15,000 |
| Maximum Amount: | Rs.1,95,000 |
Gland Pharma IPO Allotment & Listing:
| Basis of Allotment: | 17 November 2020 |
| Refunds: | 18 November 2020 |
| Credit to Demat Account: | 19 November 2020 |
| Listing Date: | 20 November 2020 |
Gland Pharma Financial:
| Rs. in Crore | |||||
| Revenue | Expense | PAT | |||
| 2016 | - | - | - | ||
| 2017 | - | - | - | ||
| 2018 | 1672 | 1170 | 321 | ||
| 2019 | 2130 | 1424 | 452 | ||
| 2020 | 2772 | 1780 | 768 | ||
Company Promoters:
- Fosun Pharma Industrial Pte. Ltd.
- Shanghai Fosun Pharmaceutical (Group) Co. Ltd.
Gland Pharma IPO Registrar:
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai - 400083
Phone: +91-22-4918 6270
Email: glandpharma.ipo@linkintime.co.in
Website: http://www.linkintime.co.in
Note: Check Gland Pharma IPO allotment status on -website allotment URL. Click Here
Gland Pharma IPO Lead Managers:
- Citigroup Global Markets India Private Limited
- Haitong Securities India Private Limited
- Kotak Mahindra Capital Company Limited
- Nomura Financial Advisory And Securities (India) Pvt Ltd
Company Address:
Gland Pharma Limited
Sy. No. 143 - 148, 150 and 151,
Near Gandi Maisamma 'X' Roads, D.P. Pally,Dundigal
Medchal-Malkajgiri District, Hyderabad
Phone: +91 40 3051 0999
Email: investors@glandpharma.com
Website: http://www.glandpharma.com
